Oncology: Value Proposition
Working together to accelerate UK cancer patient pathways.
Our Value proposition
MSD partners with NHS stakeholders and external innovators to accelerate the UK cancer patient pathway, helping trusts achieve wait time targets and improve patient experience.
To achieve this, we focus on three core areas:
Patient Pathways
MSD empowers stakeholders to achieve performance targets such as the 62-day cancer wait time and enhance patient experience. We aim to accelerate patient pathways and support the sustainability of NHS services.
Multi-Disciplinary Teams (MDTs)
By leveraging expertise and collaborative efforts, MSD enables data-driven insights to optimise workflow and streamline MDT coordination.
Pathology
We aim to alleviate workforce issues and overcome bottlenecks by analysing pathology pathways and addressing inefficiencies to speed up treatment decisions and initiation.
Get in touch
Talk to one of the team about challenges you’re facing and find out how we can help.
GB-NON-12471 | Date of Preparation: March 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
GB-NON-12852 | Date of Preparation: April 2026
Hide Footer
